<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>&lt;YOUR NAME HERE&gt; — HTBAA Fall 2026 :: 2026a-gabriela-vera</title><link>https://pages.htgaa.org/2026b/gabriela-vera/index.html</link><description>About me Contact info Homework, Labs, and Projects See the nav bar on the left to look through my work for How To Biomanufacture Almost Anything (Fall 2026)!</description><generator>Hugo</generator><language>en</language><atom:link href="https://pages.htgaa.org/2026b/gabriela-vera/index.xml" rel="self" type="application/rss+xml"/><item><title>Scalable niomanufacturing of recombinant enzymes for ex vivo conversion of group B red blood cells into ABO O-like cells</title><link>https://pages.htgaa.org/2026b/gabriela-vera/week-01-hw-project-ideas/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/gabriela-vera/week-01-hw-project-ideas/index.html</guid><description>What do I want to biomanufacture, and why? I propose the scalable biomanufacturing of a recombinant enzyme cocktail capable of removing group B antigens from donated red blood cells (RBCs), producing cells with an O-like phenotype within the ABO system. Blood group compatibility depends partly on carbohydrate antigens displayed on the RBC surface. In emergencies and blood shortages, group O RBCs are especially valuable because they lack A and B antigens. However, O-negative and other group O supplies are limited. In 2024, Jensen et al. identified exoglycosidases from the mucin-degrading gut bacterium Akkermansia muciniphila that can remove canonical and extended A and B blood group antigens. The study reported improved compatibility between enzyme-treated RBCs and group O plasma. This suggests that gut microorganisms can provide enzymes for expanding the supply of ABO-compatible blood. My proposed product is not a living bacterium administered to a patient. It is a purified recombinant enzyme cocktail used ex vivo in a controlled blood-processing system. The proposal focuses on group B RBCs because their enzymatic conversion currently appears more efficient and requires less enzyme than the conversion of group A cells. The resulting cells should be described as ABO O-like, rather than universally compatible blood, because other clinically important antigens, including Rh and Kell, would remain present.</description></item><item><title>Week 2 HW: DNA Design</title><link>https://pages.htgaa.org/2026b/gabriela-vera/week-02-hw-dna-design/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/gabriela-vera/week-02-hw-dna-design/index.html</guid><description>HTBAA Homework #2 Project: Recombinant AmGH110A for ex vivo removal of the group B antigen.&#10;Part 0: Set up in Kernel I created the repository HW2_Gabriela Vera_AmGH110A and the folder vera-amgh110a in the course workspace.&#10;Part 1: Define your expression target What molecule are you expressing?</description></item><item><title>Final Project</title><link>https://pages.htgaa.org/2026b/gabriela-vera/final-project/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/gabriela-vera/final-project/index.html</guid><description/></item></channel></rss>